Evidence map›Paper›PMID 28760729›Full record

ArticleJournal of medical Internet research2017

Using Digital Technologies in Clinical HIV Research: Real-World Applications and Considerations for Future Work.

Jessica Andriesen, Sheana Bull, Janan Dietrich, Jessica E Haberer, Barbara Van Der Pol, Yegor Voronin, Kristin M Wall, Christopher Whalen, Frances Priddy

Abstract read
In one paragraph

Article in Journal of medical Internet research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jessica AndriesenFred Hutchinson Cancer Research Center, Seattle, WA, United States.ORCID 0000-0002-2016-8500
Sheana BullColorado School of Public Health, Denver, CO, United States.ORCID 0000-0001-8688-326X
Janan DietrichPerinatal HIV Research Unit (PHRU), Faculty of Health Sciences, University of the Witwatersrand, Soweto, South Africa.ORCID 0000-0002-1949-3138
Jessica E HabererMassachusetts General Hospital/Harvard Medical School, Boston, MA, United States.ORCID 0000-0001-5845-3190
Barbara Van Der PolUniversity of Alabama at Birmingham, Birmingham, AL, United States.ORCID 0000-0003-3064-8564
Yegor VoroninGlobal HIV Vaccine Enterprise, New York, NY, United States.ORCID 0000-0003-2079-7582
Kristin M WallEmory University, Atlanta, GA, United States.ORCID 0000-0001-8547-2004
Christopher WhalenResearch Data & Communications Technologies Corp., Garrett Park, MD, United States.ORCID 0000-0002-1379-7392
Frances PriddyInternational AIDS Vaccine Initiative, New York, NY, United States.ORCID 0000-0002-2533-3982

Funding

LOC: HIV Vaccine Trials NetworkUM1AI068614 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Dan H. Barouch, Lawrence Corey · 2011 to 2026
$1175.6M
SDMC: HIV Vaccine Trials NetworkUM1AI068635 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Peter B. Gilbert, Yunda Huang · 2011 to 2026
$385.9M
NIAID NIH HHS UM1 AI068614NIAID NIH HHS UM1 AI068635
6 · The paper itself

Abstract

backgroundDigital technologies, especially if used in novel ways, provide a number of potential advantages to clinical research in trials related to human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) and may greatly facilitate operations as well as data collection and analysis. These technologies may even allow answering questions that are not answerable with older technologies. However, they come with a variety of potential concerns for both the participants and the trial sponsors. The exact challenges and means for alleviation depend on the technology and on the population in which it is deployed, and the rapidly changing landscape of digital technologies presents a challenge for creating future-proof guidelines for technology application.

objectiveThe aim of this study was to identify and summarize some common themes that are frequently encountered by researchers in this context and highlight those that should be carefully considered before making a decision to include these technologies in their research.

methodsIn April 2016, the Global HIV Vaccine Enterprise surveyed the field for research groups with recent experience in novel applications of digital technologies in HIV clinical research and convened these groups for a 1-day meeting. Real-world uses of various technologies were presented and discussed by 46 attendees, most of whom were researchers involved in the design and conduct of clinical trials of biomedical HIV prevention and treatment approaches. After the meeting, a small group of organizers reviewed the presentations and feedback obtained during the meeting and categorized various lessons-learned to identify common themes. A group of 9 experts developed a draft summary of the findings that was circulated via email to all 46 attendees for review. Taking into account the feedback received, the group finalized the considerations that are presented here.

resultsMeeting presenters and attendees discussed the many successful applications of digital technologies to improve research outcomes, such as those for recruitment and enrollment, participant identification, informed consent, data collection, data quality, and protocol or treatment adherence. These discussions also revealed unintended consequence of technology usage, including risks to study participants and risks to study integrity.

conclusionsKey lessons learned from these discussions included the need to thoroughly evaluate systems to be used, the idea that early success may not be sustained throughout the study, that some failures will occur, and considerations for study-provided devices. Additionally, taking these key lessons into account, the group generated recommendations on how to move forward with the use of technology in HIV vaccine and biomedical prevention trials.

Indexed as

HIV InfectionsHumansResearch DesignTechnologybiometric identificationclinical trialdata collectionHIVmobile phoneobservational study privacytext messaging

Identifiers

PMID28760729
PMCPMC5556256

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.